219 related articles for article (PubMed ID: 38391754)
1. Amyotrophic Lateral Sclerosis in Long-COVID Scenario and the Therapeutic Potential of the Purinergic System in Neuromodulation.
Leão Batista Simões J; Webler Eichler S; Raitz Siqueira ML; de Carvalho Braga G; Bagatini MD
Brain Sci; 2024 Feb; 14(2):. PubMed ID: 38391754
[TBL] [Abstract][Full Text] [Related]
2. Rethinking purinergic concepts and updating the emerging role of P2X7 and P2X4 in amyotrophic lateral sclerosis.
Volonté C; Amadio S
Neuropharmacology; 2022 Dec; 221():109278. PubMed ID: 36202258
[TBL] [Abstract][Full Text] [Related]
3. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
Cervetto C; Frattaroli D; Maura G; Marcoli M
Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of purinergic P2X7 receptor expression and intracellular calcium dysregulation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis.
Liu J; Prell T; Stubendorff B; Keiner S; Ringer T; Gunkel A; Tadic V; Goldhammer N; Malci A; Witte OW; Grosskreutz J
Neurosci Lett; 2016 Sep; 630():77-83. PubMed ID: 27453058
[TBL] [Abstract][Full Text] [Related]
5. Purinergic contribution to amyotrophic lateral sclerosis.
Volonté C; Apolloni S; Parisi C; Amadio S
Neuropharmacology; 2016 May; 104():180-93. PubMed ID: 26514402
[TBL] [Abstract][Full Text] [Related]
6. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
[TBL] [Abstract][Full Text] [Related]
7. Purinergic P2X
Mckenzie ADJ; Garrett TR; Werry EL; Kassiou M
ACS Chem Neurosci; 2022 May; 13(10):1479-1490. PubMed ID: 35512313
[TBL] [Abstract][Full Text] [Related]
8. Increased surface P2X4 receptors by mutant SOD1 proteins contribute to ALS pathogenesis in SOD1-G93A mice.
Bertin E; Martinez A; Fayoux A; Carvalho K; Carracedo S; Fernagut PO; Koch-Nolte F; Blum D; Bertrand SS; Boué-Grabot E
Cell Mol Life Sci; 2022 Jul; 79(8):431. PubMed ID: 35852606
[TBL] [Abstract][Full Text] [Related]
9. Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis.
Apolloni S; Amadio S; Parisi C; Matteucci A; Potenza RL; Armida M; Popoli P; D'Ambrosi N; Volonté C
Dis Model Mech; 2014 Sep; 7(9):1101-9. PubMed ID: 25038061
[TBL] [Abstract][Full Text] [Related]
10. Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives.
Cieślak M; Roszek K; Wujak M
Purinergic Signal; 2019 Mar; 15(1):1-15. PubMed ID: 30430356
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potential of P2X7 Purinergic Receptor Modulation in the Main Organs Affected by the COVID-19 Cytokine Storm.
Batista Simões JL; Sobierai LD; Pereira SM; Rodrigues Dos Santos MV; Bagatini MD
Curr Pharm Des; 2022; 28(22):1798-1814. PubMed ID: 35838210
[TBL] [Abstract][Full Text] [Related]
12. Covid-19 threat and coping: application of protection motivation theory to the pandemic experiences of people affected by amyotrophic lateral sclerosis.
Genuis SK; Luth W; Bubela T; Johnston WS
BMC Neurol; 2022 Apr; 22(1):140. PubMed ID: 35413805
[TBL] [Abstract][Full Text] [Related]
13. The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis.
Apolloni S; Parisi C; Pesaresi MG; Rossi S; Carrì MT; Cozzolino M; Volonté C; D'Ambrosi N
J Immunol; 2013 May; 190(10):5187-95. PubMed ID: 23589615
[TBL] [Abstract][Full Text] [Related]
14. Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model.
Apolloni S; Fabbrizio P; Amadio S; Napoli G; Freschi M; Sironi F; Pevarello P; Tarroni P; Liberati C; Bendotti C; Volonté C
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638992
[TBL] [Abstract][Full Text] [Related]
15. Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors.
Sebastião AM; Rei N; Ribeiro JA
Front Pharmacol; 2018; 9():267. PubMed ID: 29713276
[TBL] [Abstract][Full Text] [Related]
16. C-Boutons and Their Influence on Amyotrophic Lateral Sclerosis Disease Progression.
Wells TL; Myles JR; Akay T
J Neurosci; 2021 Sep; 41(38):8088-8101. PubMed ID: 34380764
[TBL] [Abstract][Full Text] [Related]
17. Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.
Oliveira-Giacomelli Á; Naaldijk Y; Sardá-Arroyo L; Gonçalves MCB; Corrêa-Velloso J; Pillat MM; de Souza HDN; Ulrich H
Front Pharmacol; 2018; 9():325. PubMed ID: 29692728
[TBL] [Abstract][Full Text] [Related]
18. SIMpLE: A Mobile Cloud-Based System for Health Monitoring of People with ALS.
Palumbo A; Ielpo N; Calabrese B; Corchiola D; Garropoli R; Gramigna V; Perri G
Sensors (Basel); 2021 Oct; 21(21):. PubMed ID: 34770548
[TBL] [Abstract][Full Text] [Related]
19. P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis.
Fabbrizio P; Apolloni S; Bianchi A; Salvatori I; Valle C; Lanzuolo C; Bendotti C; Nardo G; Volonté C
Brain Pathol; 2020 Mar; 30(2):272-282. PubMed ID: 31376190
[TBL] [Abstract][Full Text] [Related]
20. Management and therapeutic perspectives in amyotrophic lateral sclerosis.
Mathis S; Couratier P; Julian A; Vallat JM; Corcia P; Le Masson G
Expert Rev Neurother; 2017 Mar; 17(3):263-276. PubMed ID: 27644548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
